"Lipoproteins, IDL" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A mixture of very-low-density lipoproteins (VLDL), particularly the triglyceride-poor VLDL, with slow diffuse electrophoretic mobilities in the beta and alpha2 regions which are similar to that of beta-lipoproteins (LDL) or alpha-lipoproteins (HDL). They can be intermediate (remnant) lipoproteins in the de-lipidation process, or remnants of mutant CHYLOMICRONS and VERY-LOW-DENSITY LIPOPROTEINS which cannot be metabolized completely as seen in FAMILIAL DYSBETALIPOPROTEINEMIA.
| Descriptor ID |
D053419
|
| MeSH Number(s) |
D10.532.473 D12.776.521.514
|
| Concept/Terms |
Lipoproteins, IDL- Lipoproteins, IDL
- IDL Lipoproteins
- Lipoproteins, Intermediate Density
- Lipoprotein, IDL
- IDL Lipoprotein
- Intermediate Density Lipoproteins
- Intermediate-Density Lipoproteins
- Lipoproteins, Intermediate-Density
alpha2-Very-Low-Density Lipoproteins- alpha2-Very-Low-Density Lipoproteins
- Lipoproteins, alpha2-Very-Low-Density
- alpha2 Very Low Density Lipoproteins
- alpha2-VLDL Lipoprotein
- Lipoprotein, alpha2-VLDL
- alpha2 VLDL Lipoprotein
- alpha2-VLDL
- alpha2 VLDL
|
Below are MeSH descriptors whose meaning is more general than "Lipoproteins, IDL".
Below are MeSH descriptors whose meaning is more specific than "Lipoproteins, IDL".
This graph shows the total number of publications written about "Lipoproteins, IDL" by people in this website by year, and whether "Lipoproteins, IDL" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lipoproteins, IDL" by people in Profiles.
-
Vaziri ND, Norris KC. Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations. Blood Purif. 2013; 35(1-3):31-6.